This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trialCLARITY is a ...

A small trial enrolled 62 people with RRMS who showed signs of cognitive dysfunction to test the effectiveness of acupuncture ...

Hundreds of thousands of women will have their scans assessed by the technology in a trial that offers ‘faster access to ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

After swearing off New Year’s resolutions, CNN’s Channon Hodge follows the advice of Niecy Nash-Betts and learns to thank ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Baron Funds, an investment management company, released its “Baron Small Cap Fund” fourth-quarter 2024 investor letter. A ...

ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...

Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...

Regarding infrastructure, Weil pointed to OpenAI’s $500 billion Stargate initiative, which is aimed at expanding U.S. energy ...

The Muscular Dystrophy Association (MDA) is honoring a longtime researcher and an LGMD patient advocate with its 2025 Legacy ...